GSK Announces Vaccine Price Freeze in Support of GAVI Alliance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GSK Announces Vaccine Price Freeze in Support of GAVI Alliance


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 6

GSK reported that it would freeze the prices of its vaccines for five years for developing countries that graduate from GAVI Alliance. By committing to offer GAVI Alliance prices for vaccines against pneumococcal disease, rotavirus and cervical cancer, GSK will support developing country governments as they transition to financing the full cost of their local vaccination programs.

Since its formation in 2000, the GAVI Alliance has helped to fund the immunization of 440 million children in some of the world’s poorest countries. GSK is a long-standing partner of the Alliance and reserves its lowest prices for GAVI-eligible countries, which can be as low as one-tenth of prices in developed countries.

“By 2020, 22 countries with growing economies will graduate from GAVI support. This process allows GAVI to focus resources on the poorest countries, while enabling governments to take increasing responsibility and ownership for vaccination programs over time,” said Andrew Witty, CEO of GSK.

GSK has committed to provide more than 850 million vaccine doses that will help protect up to 300 million children and young girls in the developing world by 2024.

Source: GSK

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here